---
title: "THERMO FISHER SCIENTIFIC INC. 2026: Revenue $11.99B, EPS $4.68— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294530906.md"
description: "Thermo Fisher Scientific reported Q2 2026 results with revenue of $11.99B (+10.5% YoY) and diluted EPS of $4.68 (+9.3%). Net income reached $1.74B. Growth was driven by pharma/biotech demand, high-end instruments, and operational efficiency gains. Key contributors included Lab Products & Biopharma Services and Analytical Instruments. The company completed acquisitions like Clario to expand capabilities."
datetime: "2026-07-31T15:01:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294530906.md)
  - [en](https://longbridge.com/en/news/294530906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294530906.md)
generator: "portal-rs"
---

# THERMO FISHER SCIENTIFIC INC. 2026: Revenue $11.99B, EPS $4.68— 10-Q Summary

Thermo Fisher Scientific reported second-quarter 2026 results with revenue of $11.99B, net income of $1.74B and diluted EPS of $4.68, all up versus the prior-year quarter as the company cited strength across pharma/biotech, high-end instruments and efficiency gains.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$11.99B

$10.86B

10.5%

Net income²

$1.74B

$1.62B

7.4%

Diluted EPS³

$4.68

$4.28

9.3%

*¹ Reported as “Total revenues”. ² Reported as “Net income attributable to Thermo Fisher Scientific Inc.”. ³ Reported as “Diluted earnings per share attributable to Thermo Fisher Scientific Inc.”.*

**Business Highlights**

-   Revenue growth was broad-based, driven by pharma/biotech demand and sales of high-end instruments.
-   Strength across channels and regions, with momentum in Europe and Asia‑Pacific and gains in pharma, industrial, academic and diagnostics customers.
-   Lab Products & Biopharma Services and Analytical Instruments were key organic contributors, aided by clinical research demand and electron microscopy.
-   Completed acquisitions including Clario and filtration/separation assets to expand bioproduction and clinical research capabilities.
-   Operational productivity initiatives (PPI) delivered margin expansion despite unfavorable mix and ongoing strategic investments.

Original SEC Filing: THERMO FISHER SCIENTIFIC INC. \[ TMO \] - 10-Q - Jul. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TMO.US](https://longbridge.com/en/quote/TMO.US.md)

## Related News & Research

- [CLSA: Global Pharma Supply Chain Enters Decade-long Restructuring; Prefers Platform Leaders Including Thermo Fisher Scientific Inc , WUXI APPTEC](https://longbridge.com/en/news/297863665.md)
- [48,493 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by United Capital Financial Advisors LLC](https://longbridge.com/en/news/297307715.md)
- [Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/295995394.md)
- [Balefire LLC Sells 2,144 Shares of Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/295069344.md)
- [Farther Finance Advisors LLC Has $6.57 Million Holdings in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/296071305.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**